Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation

Pranjal Kashiv, Khushboo Saxena, Manish Ramesh Balwani, Amit Pasari, Vivek B Kute

Open source

DOI
10.5500/wjt.118000
Published
2026-09-18
Container
World Journal of Transplantation
Publisher
Baishideng Publishing Group Inc.
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.5500/wjt.118000,
  title = {Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation},
  author = {Pranjal Kashiv and Khushboo Saxena and Manish Ramesh Balwani and Amit Pasari and Vivek B Kute},
  year = {2026},
  journal = {World Journal of Transplantation},
  doi = {10.5500/wjt.118000},
  url = {https://doi.org/10.5500/wjt.118000}
}

RIS

TY  - JOUR
TI  - Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation
AU  - Pranjal Kashiv
AU  - Khushboo Saxena
AU  - Manish Ramesh Balwani
AU  - Amit Pasari
AU  - Vivek B Kute
PY  - 2026
JO  - World Journal of Transplantation
DO  - 10.5500/wjt.118000
UR  - https://doi.org/10.5500/wjt.118000
ER  - 

APA

Kashiv, P., Saxena, K., Balwani, M. R., Pasari, A., & Kute, V. B. (2026). Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation. World Journal of Transplantation. https://doi.org/10.5500/wjt.118000

Source records